keyword
MENU ▼
Read by QxMD icon Read
search

I DPP 4

keyword
https://www.readbyqxmd.com/read/28489279/dipeptidyl-peptidase-dpp-4-inhibitors-and-glucagon-like-peptide-glp-1-analogues-for-prevention-or-delay-of-type-2-diabetes-mellitus-and-its-associated-complications-in-people-at-increased-risk-for-the-development-of-type-2-diabetes-mellitus
#1
REVIEW
Bianca Hemmingsen, David P Sonne, Maria-Inti Metzendorf, Bernd Richter
BACKGROUND: The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues are able to prevent or delay T2DM and its associated complications in people at risk for the development of T2DM is unknown. OBJECTIVES: To assess the effects of DPP-4 inhibitors and GLP-1 analogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these...
May 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28476142/dipeptidyl-peptidase-4-dpp-4-inhibition-with-linagliptin-reduces-western-diet-induced-myocardial-traf3ip2-expression-inflammation-and-fibrosis-in-female-mice
#2
Annayya R Aroor, Javad Habibi, Hemanth Kumar Kandikattu, Mona Garro-Kacher, Brady Barron, Dongqing Chen, Melvin R Hayden, Adam Whaley-Connell, Shawn B Bender, Thomas Klein, Jaume Padilla, James R Sowers, Bysani Chandrasekar, Vincent G DeMarco
BACKGROUND: Diastolic dysfunction (DD), a hallmark of obesity and primary defect in heart failure with preserved ejection fraction, is a predictor of future cardiovascular events. We previously reported that linagliptin, a dipeptidyl peptidase-4 inhibitor, improved DD in Zucker Obese rats, a genetic model of obesity and hypertension. Here we investigated the cardioprotective effects of linagliptin on development of DD in western diet (WD)-fed mice, a clinically relevant model of overnutrition and activation of the renin-angiotensin-aldosterone system...
May 5, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28448177/once-weekly-dipeptidyl-peptidase-4-inhibitors-for-type-2-diabetes-a-systematic-review-and-meta-analysis
#3
Dimitrios Stoimenis, Thomas Karagiannis, Anastasia Katsoula, Eleni Athanasiadou, Kyriakos Kazakos, Eleni Bekiari, David R Matthews, Apostolos Tsapas
OBJECTIVE: To assess the efficacy and safety of omarigliptin and trelagliptin, novel dipeptidyl peptidase-4 inhibitors administered once-weekly (DPP-4i QW). METHODS: We systematically searched for placebo- and active-controlled randomized trials in adults with type 2 diabetes mellitus. RESULTS: Fifteen primary studies with 5709 participants were included. DPP-4i QW were more effective than placebo in reducing hemoglobin A1c (HbA1c) (Weighted Mean Difference (WMD) -0...
May 9, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28361153/optimized-synthesis-of-%C3%AF-extended-squaraine-dyes-relevant-to-organic-electronics-by-direct-hetero-arylation-and-sonogashira-coupling-reactions
#4
Abby-Jo Payne, Gregory C Welch
This study reports on the synthesis and characterization of four molecular π-extended squaraine compounds relevant to the field of organic electronics. The compounds each consist of a bis-indole squaraine core end-capped with indoloquinoxaline units employing three different bridging units, namely thiophene, thiazole, and acetylene. Compound 10 bears a thiophene bridge, 11 consists of a thiophene bridge and fluorinated indoloquinoxaline terminal units, and compounds 12 and 13 are bridged by thiazole and acetylene, respectively...
April 11, 2017: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/28291027/estrogen-and-dpp-4-inhibitor-share-similar-efficacy-in-reducing-brain-pathology-caused-by-cardiac-ischemia-reperfusion-injury-in-both-lean-and-obese-estrogen-deprived-rats
#5
Wasana Pratchayasakul, Sivaporn Sivasinprasasn, Piangkwan Sa-Nguanmoo, Cicely Proctor, Sasiwan Kerdphoo, Nipon Chattipakorn, Siriporn C Chattipakorn
OBJECTIVE: Cardiac ischemia-reperfusion injury (I/R) caused an oxidative burst, increased beta-amyloid production, and decreased dendritic spine density in the brain. However, the effect of cardiac I/R in the brain of estrogen-deprived rats who were or were not obese have not been investigated. Moreover, the benefits of estrogen or dipeptidyl peptidase-4 (DDP-4) inhibitor therapies in those conditions have never been determined. We hypothesized that cardiac I/R aggravates brain pathology in estrogen-deprived obese rats, to a greater extent when compared with estrogen-deprived lean rats, and treatment with either estrogen or a DPP-4 inhibitor attenuates those adverse effects...
March 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28281660/dpp-4-inhibitor-and-estrogen-share-similar-efficacy-against-cardiac-ischemic-reperfusion-injury-in-obese-insulin-resistant-and-estrogen-deprived-female-rats
#6
Sivaporn Sivasinprasasn, Pongpan Tanajak, Wanpitak Pongkan, Wasana Pratchayasakul, Siriporn C Chattipakorn, Nipon Chattipakorn
Estrogen deprivation aggravates cardiac injury after myocardial ischemia and reperfusion (I/R) injury. Although either estrogen or the dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, reduces myocardial damage following cardiac I/R, their effects on the heart in obese-insulin resistant and estrogen deprived conditions remain unknown. Ovariectomized (O) rats (n = 36) were divided to receive either normal diet (NDO) or high-fat diet (HFO) for 12 weeks, followed by treatment with a vehicle, estrogen or vildagliptin for 4 weeks...
March 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28265106/profiling-proteinic-changes-induced-by-vildagliptin-treatment-in-a-mouse-lung-transplantation-model-the-role-of-kininogen-1
#7
Zheng Tang, Wei Zhai, Zhiwei Wang, Zhipeng Hu, Min Zhang
BACKGROUND This study investigated the protective effects of pharmaceutical CD26/dipeptidylpeptidase-4 (CD26/DPP-4) inhibitor in lung transplantation (LTx). Changes in protein expression associated with the treatment were screened and identified to evaluate the role of kininogen-1 in early-term ischemia/reperfusion (I/R) injury after LTx. MATERIAL AND METHODS Orthotopic single LTx was performed in syngeneic C57BL/6 mice, with a pharmaceutical CD26/DPP-4 inhibitor (vildagliptin, subcutaneous injection, 10 mg/kg, every 12 h) administered to the investigational group...
March 7, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28251513/intensifying-treatment-beyond-monotherapy-in-type-2-diabetes-mellitus-where-do-newer-therapies-fit
#8
REVIEW
Alexander Kuhn, Jean Park, Adline Ghazi, Vanita R Aroda
PURPOSE OF REVIEW: Guidelines for a standard second diabetes medication for the treatment of type 2 diabetes (T2DM) have yet to be established. The rapid increase in the number of newer therapies available makes the choice more difficult. Thus, we reviewed clinical trial evidence evaluating newer therapies available for treatment intensification beyond monotherapy. RECENT FINDINGS: Head-to-head studies comparing newer therapies versus traditional (i.e., sulfonylurea) approaches consistently find lower incidence of hypoglycemia and weight gain with newer therapies...
March 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28251209/di-pyridyl-organic-cation-directed-hybrid-cuprous-halogenides-syntheses-crystal-structures-and-photochromism-and-photocatalysis
#9
Xiao-Wu Lei, Cheng-Yang Yue, Sai Wang, Hui Gao, Wei Wang, Ning Wang, Yun-Dong Yin
By using 1,3-di(4-pyridyl)-propane (dpp) as templates or structure-directing agents (SDAs), a series of hybrid cuprous halogenides, namely, [H2dpp]2[Cu4I8]·H2O (1), [H2dpp][Cu2I4] (2), [H2dpp]2Cu11I15 (3) and [H2dpp]2Cu11Br15 (4), have been solvothermally prepared and structurally characterized. Despite the similar chemical compositions, compound 1 features a zero-dimensional (0D) [Cu4I8](4-) unit and compound 2 contains one-dimensional (1D) [Cu2I4](2-) chains, which are both separated by [H2dpp](2+) organic cations...
March 27, 2017: Dalton Transactions: An International Journal of Inorganic Chemistry
https://www.readbyqxmd.com/read/28246236/serial-measurement-of-high-sensitivity-troponin-i-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-mellitus-in-the-examine-trial
#10
Matthew A Cavender, William B White, Petr Jarolim, George L Bakris, William C Cushman, Stuart Kupfer, Qi Gao, Cyrus R Mehta, Faiez Zannad, Christopher P Cannon, David A Morrow
Background -We sought to describe the relationship between changes in high-sensitivity cardiac troponin I (hsTnI) and cardiovascular (CV) outcomes. Methods -The Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) was a phase IIIb clinical outcomes trial designed to evaluate the CV safety of alogliptin, a non-selective dipeptidyl peptidase 4 (DPP-4) inhibitor. Patients with type 2 diabetes mellitus (T2DM), glycated hemoglobin between 6.5%-11% (or 7%-11% if they were on insulin), and a recent acute coronary syndrome (between 15-90 days prior to randomization) were eligible for the trial...
February 28, 2017: Circulation
https://www.readbyqxmd.com/read/28239736/ferrocene-diketopyrrolopyrrole-based-small-molecule-donors-for-bulk-heterojunction-solar-cells
#11
Yuvraj Patil, Rajneesh Misra, Manish Kumar Singh, Ganesh D Sharma
A symmetrical D-π-A-π-D type small molecule consisting of thiophene flanked diketopyrrolopyrrole (DPP) as a core and an end capping ferrocene donor linked by an ethynyl bridge, denoted as Fc-DPP-Fc, was synthesized and its optical, thermal and electrochemical properties were investigated in order to explore its potential applicability as a donor for solution processed bulk heterojunction solar cells. The photophysical and electrochemical properties of this small molecule showed strong charge transfer interaction between the ferrocene donor and the DPP acceptor, and it is found to be suitable as a small molecule donor along with PC71BM as an electron acceptor for solution processed bulk heterojunction organic solar cells (OSCs)...
February 27, 2017: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/28237651/gip-3-30-nh2-is-a-potent-competitive-antagonist-of-the-gip-receptor-and-effectively-inhibits-gip-mediated-insulin-glucagon-and-somatostatin-release
#12
A H Sparre-Ulrich, M N Gabe, L S Gasbjerg, C B Christiansen, B Svendsen, B Hartmann, J J Holst, M M Rosenkilde
Alternative processing of the precursor protein pro-GIP results in endogenously produced GIP(1-30)NH2, that by DPP-4 cleavage in vivo results in the metabolite GIP(3-30)NH2. We showed previously that GIP(3-30)NH2 is a high affinity antagonist of the human GIPR in vitro. Here we determine whether it is suitable for studies of GIP physiology in rats since effects of GIP agonists and antagonists are strictly species-dependent. Transiently transfected COS-7 cells were assessed for cAMP accumulation upon ligand stimulation or assayed in competition binding using human (125)I-GIP(1-42) as radioligand...
February 22, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28207538/comparison-of-baseline-characteristics-and-clinical-course-in-japanese-patients-with-type-2-diabetes-among-whom-different-types-of-oral-hypoglycemic-agents-were-chosen-by-diabetes-specialists-as-initial-monotherapy-jddm-42
#13
Kazuya Fujihara, Risa Igarashi, Satoshi Matsunaga, Yasuhiro Matsubayashi, Takaho Yamada, Hiroki Yokoyama, Shiro Tanaka, Hitoshi Shimano, Hiroshi Maegawa, Katsuya Yamazaki, Koichi Kawai, Hirohito Sone
Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial therapy by diabetes specialists for patients with type 2 diabetes. Moreover, there has been little clarification of the subsequent usage patterns and related factors that influenced the continuation or discontinuation of the drug or the addition of another drug. To provide information on these issues, we evaluated the clinical characteristics of Japanese patients with type 2 diabetes for whom different types of oral hypoglycemic agents (i...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28183314/dpp-4-inhibition-has-no-acute-effect-on-bnp-and-its-n-terminal-pro-hormone-measured-by-commercial-immune-assays-a-randomized-cross-over-trial-in-patients-with-type-2-diabetes
#14
Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani, Angelo Avogaro
BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD)...
February 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28182722/hemoglobin-glycation-index-as-a-useful-predictor-of-therapeutic-responses-to-dipeptidyl-peptidase-4-inhibitors-in-patients-with-type-2-diabetes
#15
Yu-Wei Chen, Jun-Sing Wang, Wayne H-H Sheu, Shih-Yi Lin, I-Te Lee, Yuh-Min Song, Chia-Po Fu, Chia-Lin Lee
INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level...
2017: PloS One
https://www.readbyqxmd.com/read/28160554/pharmacogenetics-of-dipeptidyl-peptidase-4-inhibitors-in-a-taiwanese-population-with-type-2-diabetes
#16
Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang, Fuu-Jen Tsai
Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors' advantages, the patients' therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free genome-wide association study, 45 single nucleotide polymorphisms (SNPs) involved in the therapeutic response to DPP-4 inhibitors (P < 1 × 10-4) were identified at or near PRKD1, CNTN3, ASK, and LOC10537792...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28150162/workplace-interventions-to-prevent-type-2-diabetes-mellitus-a-narrative-review
#17
REVIEW
Dina Hafez, Allison Fedewa, Margaret Moran, Matthew O'Brien, Ronald Ackermann, Jeffrey T Kullgren
PURPOSE OF REVIEW: This study aims to summarize the recent peer-reviewed literature on workplace interventions for prevention of type 2 diabetes mellitus (T2DM), including studies that translate the Diabetes Prevention Program (DPP) curriculum to workplace settings (n = 10) and those that use different intervention approaches to achieve the specific objective of T2DM prevention among employees (n = 3). RECENT FINDINGS: Weight reduction was achieved through workplace interventions to prevent T2DM, though such interventions varied substantially in their effectiveness...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28142080/new-copper-i-and-heteronuclear-copper-i-ruthenium-ii-complexes-synthesis-structural-characterization-and-cytotoxicity
#18
João Lopes, David Alves, Tânia S Morais, Paulo J Costa, M Fátima M Piedade, Fernanda Marques, Maria J Villa de Brito, M Helena Garcia
A new family of copper(I) complexes of general formula [Cu(dppe)(NN)](+) have been synthesized and fully characterized, with dppe=1.2-bis(diphenylphosphino)ethane and NN representing several bidentate heteroaromatic ligands: 2,2'-bipy=2.2'-bipyridine (1), Me2bpy=4.4'-dimethyl-2,2'-bipyridine (2), dpytz=3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine (3), dpp=2.3-bis(2-pyridyl)pyrazine (4), and the metallaligand [Ru(η(5)-C5H5)(PPh3)(dpp)](+) (5), yielding the bimetallic copper(I)-ruthenium(II) complex [Cu(dppe)(μ-dpp)Ru(η(5)-C5H5)(PPh3)](2+) (6)...
April 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28127851/impact-of-insulin-sensitivity-beta-cell-function-and-glycemic-control-on-initiation-of-second-line-glucose-lowering-treatment-in-newly-diagnosed-type-2-diabetes
#19
Wolfgang Rathmann, Klaus Strassburger, Brenda Bongaerts, Pavel Bobrov, Oliver Kuss, Karsten Müssig, Daniel F Markgraf, Julia Szendroedi, Christian Herder, Michael Roden
AIMS: The aim was to investigate whether insulin sensitivity, beta-cell function or glycemic control at diagnosis predict initiation of second-line treatment in newly diagnosed type 2 diabetes. MATERIAL AND METHODS: Type 2 diabetes patients (n = 138) on initial metformin monotherapy (age [mean ± SD]: 52 ± 10 years; 67% males; BMI: 32 ± 6 kg/m(2) ) from the prospective German Diabetes Study cohort (n = 398) were included. Patients remained under treatment of their general practitioners, yet underwent detailed metabolic characterization after diabetes diagnosis for study purposes (hyperinsulinemic-euglycemic clamp: M value; i...
January 27, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28116795/novel-oral-glucose-lowering-drugs-are-associated-with-lower-risk-of-all-cause-mortality-cardiovascular-events-and-severe-hypoglycaemia-compared-with-insulin-in-patients-with-type-2-diabetes
#20
Thomas Nyström, Johan Bodegard, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W Eriksson
AIMS: To investigate the association of novel oral glucose-lowering drugs (GLDs), compared with that of insulin, with risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. METHODS: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs, either dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT2) inhibitors (only dapagliflozin available in Sweden during the study period), with those initiating insulin as a comparison group, in the Prescribed Drug Register were included and followed in the Patient and Cause of Death Registers...
January 24, 2017: Diabetes, Obesity & Metabolism
keyword
keyword
110953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"